Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies

NEW YORK, Dec. 31, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies

http://www.reportlinker.com/p01054398/Competitor-Analysis-Biosimilar-and-Biosuperior-Therapeutic-Antibodies.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical

Product description

The present Competitive Intelligence Report about Biosimilar and Biosuperior Therapeutic Antibodiesprovides a competitor evaluation in the field of recombinant monoclonal and polyclonal antibodies in the market, in the pipeline as next generation products and as biosimilar versions as of December 2012. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Marketed antibodies are attractive for companies to create next generation variants and  biosimilar copies because they represent clinically and commercially validated products. New technologies such as Fc engineering, polyclonal mixtures, antibody drug conjugates or bispecific molecules as well as the expiration of patents stimulate the discovery and development of biosimilar and biosuperior/biobetter molecules. The cumulated sales volume of therapeutic antibodies for which biosmilar antibodies are in the R&D pipeline was as high as US$ 54.7 bln in the year 2011 with double digit growth rates of many representative of them:

Rituxan/MabThera

Arzerra

Erbitux

Vectibix

Herceptin

Avastin

Lucentis

Enbrel

Remicade

Humira

Cimzia

Simponi

Actemra/RoActemra

ReoPro

Campath

Orencia

Tysabri

Xolair

Synagis

Prolia/Xgeva

Soliris

Stelara

Zenapax

More than 140 biosimilar antibodies are in the pipeline with the first molecules approved in non-regulated markets. Ther regulation of the development of biosimilar antibodies in the European Union has facilitated the submission of an MAA of a first biosimilar antibody from a Korean company.

The report includes a compilation of currently active projects in research and development of biosimilar and biosuperior antibodies against commercially and clinically validated targets:

CD20

Her2

VEGF

TNF

EGF-R

CD52

GPIIb/IIIa

B7.1/B7.2 (CD80/CD86)

IL-6R

Alpha4/beta1/7 integrin

IgE

RSV

RANKL

Complement C5

IL-12/IL-23

CD25 (IL-2R)

Competitor projects are listed in a tabular format providing information on:

-Drug Codes,

-Target / Mechanism of Action,

-Class of Compound,

-Company,

-Product Category,

-Indication,

-R&D Stage and

-additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table of Contents

CD20 Antibodies

1. Marketed CD20 Antibodies & Sales

Rituxan/MabThera Pipeline & Sales

Arzerra Pipeline & Sales

Zevalin Pipeline & Sales

Bexxar 

2. Biosuperior CD20 Antibodies

Bispecific CD20 Antibodies

3. Biosimilar CD20 Antibodies

Rituximab (Erbitux) Biosimilars

Ofatumumab (Arzerra) Biosimilars

EGF-R Antibodies

1. Marketed EGF-R Antibodies & Sales

Erbitux Pipeline & Sales

Vectibix Pipeline & Sales

Nimotuzumab Pipeline

2. Biosuperior EGF-R Antibodies

3. Biosimilar EGF-R Antibodies

Cetuximab (Erbitux) Biosimilars

Panitumumab (Vectibix) Biosimilars

Her2 Antibodies

1. Marketed Her2 Antibodies & Sales

Herceptin Pipeline & Sales

Next Generation Herceptin: Pertuzumab Pipeline

2. Biosuperior Her2 Antibodies

T-DM1 Pipeline

Other Her2 Antibody-Drug Conjugates

Her2 Bispecific Antibodies

Engineered Her2 Antibodies

Imaging Her2 Antibodies

3. Biosimilar Her2 Antibodies

Trastuzumab (Herceptin) Biosimilars

VEGF Antibodies: Avastin

1. Marketed VEGF Antibody & Sales

Avastin Pipeline & Sales

2. Biosuperior VEGF Antibodies

Anti-VEGF Antibody Pipeline

Anti-VEGF-R Antibody Pipeline

Bispecific Anti-VEGF Pipeline

3. Biosimilar VEGF Antibodies

Bevacizumab (Avastin) Biosimilars

VEGF Antibodies: Lucentis

1. Marketed VEGF Antibody & Sales

Lucentis Pipeline & Sales

2. Biosuperior VEGF Antibodies

Next Generation Lucentis Pipeline

3. Biosimilar VEGF Antibodies

Ranibizumab (Lucentis) Biosimilars

TNF Antibodies

1. Marketed TNF Antibodies & Sales

Enbrel Pipeline & Sales

Remicade Pipeline & Sales

Humira Pipeline & Sales

Cimzia Pipeline & Sales

Simponi Pipeline & Sales

2. Biosuperior TNF Antibodies

Biosuperior TNF Antibodies

3. Biosimilar Her2 Antibodies

Etanercept (Enrel) Biosimilars

Infliximab (Remicade) Biosimilars

Adalimumab (Humira) Biosimilars

Certolizumab pegol (Cimzia) Biosimilars

Golimumab (Simponi) Biosimilars

IL-6R Antibodies

1. Marketed IL-6R Antibody & Sales

Actemra Pipeline & Sales

2. Biosuperior IL-6R Antibodies

Biosuperior IL-6R Antibodies

3. Biosimilar VEGF Antibodies

Tocilizumab (Actemra) Biosimilars

GPIIb/IIIa Antibodies

1. Marketed GPIIb/IIIa Antibody & Sales

ReoPro Pipeline & Sales

2. Biosimilar GPIIb/IIIa Antibodies

Abciximab (ReoPro) Biosimilars

CD52 Antibodies

1. Marketed CD52 Antibody 

Campath Pipeline & Sales

2. Biosimilar CD52 Antibodies

Alemtuzumab (Campath) Biosimilars

CD80/CD86 (B7.1/B7.2) Antibodies

1. Marketed CD80/86 (B7-1/B7-2) Antibodies & Sales

Orencia Pipeline & Sales

2. Biosuperior CD80/86 (B7-1/B7-2) Antibodies

Biosuperior CD80/86 (B7-1/B7-2) Antibodies

3. Biosimilar CD80/86 (B7-1/B7-2) Antibodies

Abatacept (Orencia) Biosimilars

Alpha4/beta1/7 Integrin Antibodies

1. Marketed Alpha4/beta1/7 Integrin Antibody 

Tysabri Pipeline & Sales

2. Biosimilar Alpha4/beta1/7 Integrin Antibodies

Natalizumab (Tysabri) Biosimilars

IgE Antibodies

1. Marketed IgE Antibodies & Sales

Xolair Pipeline & Sales

2. Biosuperior IgE Antibodies

Biosuperior IgE Antibodies

3. Biosimilar IgE Antibodies

Omalizumab (Xolair) Biosimilars

RSV Antibodies

1. Marketed RSV Antibodies & Sales

Synagis Pipeline & Sales

2. Biosuperior RSV Antibodies

Biosuperior RSV Antibodies

3. Biosimilar RSV Antibodies

Palivizumab (Synagis) Biosimilars

RANKL Antibodies

1. Marketed RANKL Antibodies & Sales

Prolia/XGEVA Pipelines & Sales

2. Biosuperior RANKL Antibodies

Biosuperior RANKL Antibodies

3. Biosimilar RANKL Antibodies

Denosumab (Prolia / XGEVA) Biosimilars

Complement C5 Antibodies

1. Marketed Complement C5 Antibodies & Sales

Soliris Pipelines & Sales

2. Biosuperior Complement C5 Antibodies

Biosuperior Complement C5 Antibodies

3. Biosimilar Complement C5 Antibodies

Eculizumab (Soliris) Biosimilars

IL-12/IL-23 Antibodies

1. Marketed IL-12/IL-23  Antibody 

Stelara Pipeline & Sales

2. Biosimilar IL-12/IL-23  Antibodies

Ustekinumab (Stelara) Biosimilars

CD25 (IL-2R) Antibodies

1. Marketed CD25 (IL-2R) Antibodies 

Zenapax Pipeline 

2. Biosuperior CD25 (IL-2R) Antibodies

Biosuperior CD25 (IL-2R) Antibodies

3. Biosimilar CD25 (IL-2R) Antibodies

Daclizumab (Zenapax) Biosimilars

To order this report:

Biopharmaceutical Industry: Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies

Contact Nicolas: nicolasbombourg@reportlinker.com
US: (805)-652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.